NCT05745727View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, PK, and PD Properties of PRX-115 in Adult Volunteers With Elevated Uric Acid Levels

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

March 23, 2023

Primary Completion Date

August 26, 2024

Study Completion Date

February 6, 2025

Conditions
Gout
Interventions
DRUG

PRX-115

Escalating doses of PRX-115 will be given in different cohorts i.e., Cohorts 1 through 8

DRUG

Placebo

Escalating doses of Placebo will be given in different cohorts i.e., Cohorts 1 through 8

Trial Locations (2)

1010

New Zealand Clinical Research, Grafton

8011

New Zealand Clinical Research, Christchurch

All Listed Sponsors
lead

Protalix

INDUSTRY